Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $118.10

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average recommendation of “Moderate Buy” from the twenty-three ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, twenty-one have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $117.1364.

Several research analysts recently commented on the company. BTIG Research reduced their price target on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research report on Monday, June 8th. Morgan Stanley reissued an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Stephens increased their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Finally, Jefferies Financial Group assumed coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 price target for the company.

Kymera Therapeutics Price Performance

KYMR stock opened at $86.21 on Friday. The business has a 50-day moving average of $82.85 and a 200-day moving average of $80.22. Kymera Therapeutics has a fifty-two week low of $36.65 and a fifty-two week high of $103.00. The stock has a market capitalization of $7.09 billion, a P/E ratio of -24.15 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million during the quarter, compared to analysts’ expectations of $8.27 million. During the same period in the prior year, the firm posted ($0.82) earnings per share. The business’s quarterly revenue was up 55.5% compared to the same quarter last year. Equities analysts expect that Kymera Therapeutics will post -3.25 EPS for the current year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Elena Ridloff sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $87.00, for a total value of $261,000.00. Following the sale, the director owned 3,000 shares in the company, valued at $261,000. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $81.18, for a total value of $2,435,400.00. Following the completion of the sale, the chief executive officer owned 666,195 shares in the company, valued at $54,081,710.10. This represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 234,357 shares of company stock worth $19,072,496 over the last ninety days. 15.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of KYMR. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Kymera Therapeutics by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after buying an additional 1,833 shares during the period. Millennium Management LLC raised its stake in Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after buying an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Kymera Therapeutics by 121.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. Invesco Ltd. increased its stake in shares of Kymera Therapeutics by 13.8% during the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after purchasing an additional 5,809 shares during the period. Finally, Sei Investments Co. bought a new position in shares of Kymera Therapeutics during the second quarter worth approximately $265,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.